OTC: RSMDF - ResMed Inc.

Yield per half year: -7.14%
Sector: Healthcare

ResMed Inc.

Underestimation

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
P/E
10/10
2.56 117.69 -97.83% 25.04 -89.78%
P/S 0.5574 8.16 -93.17%
P/BV 0.5369 3.37 -84.07%
P/FCF 18.94 160.84 -88.22%
Ev/Ebitda 2.03 52.39 -96.13%
Ev/S 0.6931 6.96 -90.05%
Ev/FCF 2.52 142.77 -98.23%
E/P 0.0419 1.47 -97.15%

Efficiency

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
Ebitda margin
9/10
34.16 24.93 36.99% 31.98 +6.82%
ROE 20.99 12.96 61.95%
ROA 14.86 6.09 143.84%
ROIC 21.1 15.56 35.59%
ROS 21.79 12.55 73.61%
ROCE 28.46 16.88 68.55%

Debt

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
Debt/Ebitda
10/10
0.4577 143.57 -99.68% 0.4475 +2.28%
Nеt Debt/Ebitda 0.3972 -5.05 -107.86%
Debt/Ratio 0.1066 0.4053 -73.7%
Debt/Equity 1.1 11.8 -90.67%
Debt/Net Income 0.7175 147.58 -99.51%

Dividends

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
Dividend yield
4.23/10
1.69 1.73 -2.55% 1.41 +19.65%
Number of years of dividend growth 5 1.07 367.11%
DSI 1 0.7807 28.08%
Average dividend growth 18.92 -79.6 -123.77%
Average percentage for 5 years 1.41 2.81 -49.78%
Average percentage for payments 52.19 247.07 -78.87%
Difference from average difference in sector -0.0442

Growth impulse

Parameter Grade Value Sector average Difference with sector, %
Growth impulse Revenue in 5 years
7/10
58.45 180.62 -67.64%
Growth impulse Ebitda in 5 years 67.57 201.95 -66.54%
Growth impulse Net Income in 5 years 64.14 160.03 -59.92%
Growth impulse FCF in 5 years 84.83 118.65 -28.5%
Growth impulse EPS in 5 years 1547.47 280.49 451.7%
IP Score
8.13/10

Similar companies

Sinopharm Group Co., Ltd.

Novartis AG

Ono Pharmaceutical Co., Ltd.

CSPC Pharmaceutical Group Limited

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription